X
Mnesys - Pubblications

 

December 29, 2025

Modulation of ZnT-1 by Let7a unveils a therapeutic potential in amyotrophic lateral sclerosis

Progetti: Progettazione, sintesi, caratterizzazione e formulazione di ligandi innovativi del TSPO come regolatori della risposta infiammatoria microgliale per uso terapeutico nelle demenze , Caratterizzazione di un modello tossicologico murino di SLA mediante esposizione alla tossina L BMAA

The imbalance in cellular ionic homeostasis represents a hallmark of several neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS). Zinc Transporter 1 (ZnT1), the first described member of the ZnT family, stands out as the sole member of the SLC30 family responsible for exporting cytosolic zinc to the extracellular space. While ZnT1 is expressed across all tissues and cell types studied, it exhibits the highest prominence within the central nervous system. In ALS SOD1G93A mice, a reduction in ZnT1 expression consistent with disease progression has been observed, prompting our investigation into its role in ALS pathophysiology. Remarkably, through the use of a sequence complementary to the microRNA let-7a (anti-Let-7a) able to modulate ZnT1 expression, we demonstrated in ALS mice its capability to: (1) prevent the reduction in ZnT1 levels in the spinal cord; (2) preserve motor neuron survival in the ventral spinal horn; (3) decrease astroglial and microglial activation while sparing resident microglial cells in the spinal cord; and (4) improve the lifespan and alleviate motor symptoms.

Authors

Giusy Laudati

Giusy Laudati

Giuseppe Pignataro

Giuseppe Pignataro

Other Authors

Serenella Anzilotti, Cristina Franco, Valeria Valsecchi, Ornella Cuomo, Giovanna Lombardi, Noemi Di Muraglia, Nunzia De Iesu, Lucio Annunziato, Lorella Maria Teresa Canzoniero